{"name":"Vanda Pharmaceuticals","slug":"vanda","ticker":"VNDA","exchange":"NASDAQ","domain":"vandapharma.com","description":"Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesi","hq":"Washington, DC","founded":0,"employees":"533","ceo":"Mihael H. Polymeropoulos, M.D.","sector":"CNS / Specialty Pharma","stockPrice":6.46,"stockChange":0.03,"stockChangePercent":0.47,"marketCap":"$388M","metrics":{"revenue":217782000,"revenueGrowth":3.4,"grossMargin":94.2,"rdSpend":109271000,"netIncome":-220474000,"cash":202310000,"dividendYield":0,"peRatio":32.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Fanapt patent cliff ($0.0B at risk)","drug":"Fanapt","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"HETLIOZ patent cliff ($0.0B at risk)","drug":"HETLIOZ","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Milsaperidone","genericName":"Milsaperidone","slug":"milsaperidone","indication":"Other","status":"marketed"},{"name":"Iloperidone and VHX-896","genericName":"Iloperidone and VHX-896","slug":"iloperidone-and-vhx-896","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Milsaperidone","genericName":"Milsaperidone","slug":"milsaperidone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iloperidone and VHX-896","genericName":"Iloperidone and VHX-896","slug":"iloperidone-and-vhx-896","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Vanda Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $143.1 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Vanda Pharmaceuticals Announces Exclusive Distribution Agreement with Sandoz for HETLIOZ in the United States","summary":"Vanda Pharmaceuticals announced an exclusive distribution agreement with Sandoz for HETLIOZ in the United States.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Vanda Pharmaceuticals Receives FDA Approval for HETLIOZ for the Treatment of Non-24-Hour Sleep-Wake Disorder","summary":"Vanda Pharmaceuticals received FDA approval for HETLIOZ for the treatment of non-24-hour sleep-wake disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBfellnbGJVYlhMRU44NVlCSEJCVmFOYUllVU41Sm1DTHFqZWV1YmFZNVRYMWpEUjJxZzlCTUU5R0xRNENHN2tPUHBTazNhN2RUOEEzMTFteUlaOXpFa2M4NXp4bjhNcmpKdXMxS01B?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan","headline":"If You Invested $1,000 in Vanda Pharma (VNDA)","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOeHJwUVpQWHItdzlVMDhUMzVobThYMmJ4VGJVcm91cjg4RmZlX1g4UkJNSUUwSTQ2QmhOQXdDYVRpTEhpNURzT3VOZFFkTXdSN1RjQmxmdUtNZzhwSWhYYUY5UXRuRy1PNk41ajNoRjlONXI0N1dMT2x4RFBwcno3amsyeVRXVmpSMFo5NGdZczgydmFUV0szSjkyNTdGdTNXOG9sT3ZkaGdvVWJzWHdpTTk3dWFkOFJtQnhOelhEN1dkLTJBeGx0aWJSU1E0SHJXLU5YN2c0RmtVS1FPeG9RZA?oc=5","date":"2026-02-26","type":"pipeline","source":"PR Newswire","summary":"Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - PR Newswire","headline":"Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSk5IN25VOV8tS1ZyazdpeWEyUG1EcmhOUjRUSUVPVERlZ3ZJenNvZ2tocXlkVnB2WlJrT056d3dLQUxVNTVpNEtqeExxVThDbFpIdkFyLTRwYTY2MU9vRDBCRWtPblc2c3JnR0MzaXY3VEtJY1Z2OE1aT1Y0blA2Q0xSajRkajF0TWI3ZDVPU1hQRXQ1R0x5bktIQQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Benzinga","summary":"What's Going On With Vanda Pharma Stock Tuesday? - Benzinga","headline":"What's Going On With Vanda Pharma Stock Tuesday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOemdBZTFnYlE4M09YTnZNWjY3MGt6eVVJakpwdjZiQzJMQ2JkRHJQQ2l1Sjh5cGUtNjJzbzBrTVlqNEN6QTZTcTBkZEdONWpTUVRZQ1psRFU3REctQ0RZNkF3QTFMZHRCMEI5WVdoWm1tVE1YM0NMNVRkdnZHamtKcTYyUHVuejRVYjlSTC13d3IweHdyUWtvTnhBdHY4aU9rcDZtNDhtcmlFM3VBeTJFcTJqTTdHMG1GSlE?oc=5","date":"2026-02-23","type":"regulatory","source":"Seeking Alpha","summary":"Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy (VNDA) - Seeking Alpha","headline":"Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy (VNDA)","sentiment":"positive"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQSDlmRFdmTXVsdGgyTWk4R01jMWxySU1tajlubU1ETVIyVEFVejlIS3pZLWtXNHJRVHd3T3lQbDZiV1RlZFFIdVF2Tk5sTkhRSUdqSU16VUZTcHM4bWV3V3MzQzR6RFMydzg4SGVtZVRLVEpaTGc4WnJRWWRJRmc5bXlBeFBINE16TDBnODU4WlR0aUlVY0tWLW9kZ2FSa1IwQUF5VnduS2JMcnJNbEE1S2xB?oc=5","date":"2026-02-20","type":"trial","source":"Stock Titan","summary":"New bipolar and schizophrenia drug builds on 100,000 patient-years of data - Stock Titan","headline":"New bipolar and schizophrenia drug builds on 100,000 patient-years of data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWWRTRTM1T1Zxak80U0NnMkhEdkRTQUNlYUlpQzlsM2Z3Wk1vTGgzTGpfUE95d201QVpjcjBkdjE5Zm1ieEpBN2NvcTNlYkpGYjgwMlBkcUNXNnlNWGVqN3ZzRVZLa0h3TWZDWFRqcE8tbFdYZmwxY3ZDaWlWWE9tWmR1LW5yZHdkTGJYeDA1NXR4aC1CZklRM21EVnRSWkZHaU1pUWZnaUJRa0Nid3l3?oc=5","date":"2026-02-19","type":"pipeline","source":"Seeking Alpha","summary":"Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA) - Seeking Alpha","headline":"Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week (NASDAQ:VNDA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOWmg5bzI0eHVXT0gtUE5FcDBPcmdwZndSWkpoVmc1ejZIMHY5b0k2Rmpta3lUZ05CTVpKMkVBYm9EOVhYdmZlX0FidHF6czJRRHlaYUxZRFRXNnBpNUlCYU12U2tDd1lLVTFyZXpQZ1FGbl9qS2JGMnNZUklSVDl3S0J0bHA3RnFvcGRQSEFCOGczY2lveVJ3VlZBdXk4TE02Y2pSSlhjSlAyQlh4MkRVdnVXSUZuYXdHT25mU0pzaw?oc=5","date":"2026-02-04","type":"earnings","source":"Stock Titan","summary":"Vanda sets Feb. 11 call on Q4 and full-year 2025 results - Stock Titan","headline":"Vanda sets Feb. 11 call on Q4 and full-year 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPd3Q1ZklnenM4QTB6OTUybzB2aDVtRkd0NUZ0TWlRWHRubjBWd3FyWVJoNENjdVcySkxLNmhsd3NjMnVhOEg0MjZXX2tkcGF2MHFQdzhLY2NNMWRqc0lEZFNmckpra3RONmNzWnhuM25VS01CMm0ydzhyLXVlU0ZtaGZldndZdVVVRDZnT1cweVJ2SGppcEpCUHRIT0E2WWtiV1V0RENQaw?oc=5","date":"2026-01-02","type":"pipeline","source":"Seeking Alpha","summary":"Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha","headline":"Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPZUo4cFF6a3NFMkFGZzNuNE14amNoYmFnajlXaFNFMUlZTGRkcVRvZGV4SWRnNFJvRzF1WmJpV0hCOFV5UFF3Q0ZydzR4SFdYVzg1THEwcHFocUptbkpIZWRxU25ZUTk1cTM1N3FtNFRHcVl2SE1CaWd5SDg0d3BnVXdndlhKRXVfZ3lSZGR5cWtub0JPdHRFSEVBTzkydjNjdFE4YWE1WG9TS0I2WnhKazZpNXRkbzd2eHZLeFpmVHNaamtsSktKcF96Zldzdzk3cjBJMzdzc29temxCaEZDcFZ1U3d5NFMyMER3TXhkT1hiUjB5VHpZRGtzbnliV2ZrYTFlUWFtRzRwR1BGelJnbGRsdEhHRGxJclBOaVRGcw?oc=5","date":"2025-12-15","type":"regulatory","source":"PR Newswire","summary":"Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire","headline":"Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNX1ZSSE8yemZLZlZ1bmR4YVNPUnM1LS05a1FKVlRHdGlrUmpKTTk2MUdKRVBCNXl3Z1lvRFFVOVBqaFpTY1pGYnhkWnZBTWFGSEp2OUUtTFZiTGZFTU1fVHcyRklYYWF4Wi1NbGxkY3V6NEFlbWRaQlZKMUNrY3FsOFpvT1kxdXI4dS0xRGJ0MW1hVDNSa28xQWJ3S2ZOU1VPOVhHQ09TSS1Ya0xBbFRuT0RWS0xzRzBuMEI2clpWOA?oc=5","date":"2025-10-29","type":"earnings","source":"PR Newswire","summary":"Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - PR Newswire","headline":"Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRXBiVTV2eDU2YzNmSTRYNWFrRlJXeHJHN0FUMGRoMmtGVVB4TUFkSTVhaGhlb3dLWW5Rb2NmeTRsbGxWU2JFZC1id0hMZkd0VzhoUnBCZ0RBLU9XMmpPVnAyT3JXU28zRzhZTGJOM1kzYmVuWVpaOHB1YVhsdGJpUnA4VFloQVBOQkdWVjlkRUlIY0ZSaVBYSlNpaVFrQmQxZ1NzVHhaN3N1VUxaRTNOU3FFVlU?oc=5","date":"2025-10-01","type":"regulatory","source":"Stock Titan","summary":"Major Regulatory Breakthrough: Vanda Pharmaceuticals Secures FDA Fast-Track Review for Multiple Drugs - Stock Titan","headline":"Major Regulatory Breakthrough: Vanda Pharmaceuticals Secures FDA Fast-Track Review for Multiple Drugs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-24","type":"trial","source":"PR Newswire","summary":"Vanda Pharmaceuticals announces the publication in PLOS One of an article titled \"Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, ","headline":"Vanda Pharmaceuticals announces the publication in PLOS One of an article titled \"Melatonin agonist tasimelteon (HETLIOZ","sentiment":"neutral"}],"patents":[{"drugName":"Fanapt","drugSlug":"iloperidone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"HETLIOZ","drugSlug":"tasimelteon","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sunovion Pharmaceuticals","Pfizer Inc.","Takeda Pharmaceutical Company"],"therapeuticFocus":["CNS","Sleep Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":216105000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":216105000,"period":"2025-12-31"},{"value":198772000,"period":"2024-12-31"},{"value":198772000,"period":"2024-12-31"},{"value":192640000,"period":"2023-12-31"},{"value":192640000,"period":"2023-12-31"}],"grossProfit":203061000,"grossProfitHistory":[{"period":"2025-12-31","value":203061000},{"period":"2024-12-31","value":187458000},{"period":"2023-12-31","value":177844000},{"period":"2022-12-31","value":230100000}],"rdSpend":109271000,"rdSpendHistory":[{"period":"2025-12-31","value":109271000},{"period":"2024-12-31","value":74431000},{"period":"2023-12-31","value":76823000},{"period":"2022-12-31","value":85770000}],"sgaSpend":237951000,"operatingIncome":-151168000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-151168000},{"period":"2024-12-31","value":-40660000},{"period":"2023-12-31","value":-13952000},{"period":"2022-12-31","value":6329000}],"netIncome":-220474000,"netIncomeHistory":[{"period":"2025-12-31","value":-220474000},{"period":"2024-12-31","value":-18900000},{"period":"2023-12-31","value":2509000},{"period":"2022-12-31","value":6275000}],"eps":-3.74,"epsHistory":[{"period":"2025-12-31","value":-3.74},{"period":"2024-12-31","value":-0.33},{"period":"2023-12-31","value":0.04},{"period":"2022-12-31","value":0.11}],"cash":84851000,"cashHistory":[{"period":"2025-12-31","value":84851000},{"period":"2024-12-31","value":102316000},{"period":"2023-12-31","value":135821000},{"period":"2022-12-31","value":135029000}],"totalAssets":488948000,"totalLiabilities":161762000,"totalDebt":12622000,"equity":327186000,"operatingCashflow":-109442000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-109442000},{"period":"2024-12-31","value":-15757000},{"period":"2023-12-31","value":12801000},{"period":"2022-12-31","value":31984000}],"capex":-998000,"capexHistory":[{"period":"2025-12-31","value":-998000},{"period":"2024-12-31","value":-490000},{"period":"2023-12-31","value":-383000},{"period":"2022-12-31","value":-679000}],"freeCashflow":-110440000,"dividendsPaid":null,"buybacks":null,"employees":533,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":62978000,"ebit":-40353000,"ebitda":-34490000,"period":"2025-12-31","revenue":57216000,"epsBasic":-2.39,"netIncome":-141187000,"rdExpense":29006000,"epsDiluted":-2.39,"grossProfit":53383000,"operatingIncome":-40353000},{"sga":60273000,"ebit":-31284000,"ebitda":-29231000,"period":"2025-09-30","revenue":56258000,"epsBasic":-0.38,"netIncome":-22586000,"rdExpense":22563000,"epsDiluted":-0.38,"grossProfit":53304000,"operatingIncome":-31284000},{"sga":64616000,"ebit":-38503000,"ebitda":-36485000,"period":"2025-06-30","revenue":52590000,"epsBasic":-0.46,"netIncome":-27207000,"rdExpense":21990000,"epsDiluted":-0.46,"grossProfit":49854000,"operatingIncome":-38503000},{"sga":50084000,"ebit":-41028000,"ebitda":-39045000,"period":"2025-03-31","revenue":50041000,"epsBasic":-0.5,"netIncome":-29494000,"rdExpense":35712000,"epsDiluted":-0.5,"grossProfit":46520000,"operatingIncome":-41028000},{"sga":39282000,"ebit":-10279000,"ebitda":-8306000,"period":"2024-12-31","revenue":53185000,"epsBasic":-0.08,"netIncome":-4912000,"rdExpense":19840000,"epsDiluted":-0.08,"grossProfit":50595000,"operatingIncome":-10279000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.46,"previousClose":6.43,"fiftyTwoWeekHigh":9.94,"fiftyTwoWeekLow":3.81,"fiftyTwoWeekRange":"3.81 - 9.94","fiftyDayAverage":7.39,"twoHundredDayAverage":6.18,"beta":0.65,"enterpriseValue":197434656,"forwardPE":32.3,"priceToBook":1.17,"priceToSales":1.78,"enterpriseToRevenue":0.91,"enterpriseToEbitda":-1.3,"pegRatio":0,"ebitda":-151976992,"ebitdaMargin":-69.8,"freeCashflow":-83154496,"operatingCashflow":-126513000,"totalDebt":13073000,"debtToEquity":4.7,"currentRatio":2.16,"returnOnAssets":-18.8,"returnOnEquity":-60.5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":14.9,"targetHighPrice":21,"targetLowPrice":7.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.2,"institutionHeldPercent":72.9,"sharesOutstanding":60135562,"floatShares":54199581,"sharesShort":6196446,"shortRatio":5.72,"shortPercentOfFloat":10.3,"epsTrailing":-4.06,"epsForward":0.2,"revenuePerShare":3.68,"bookValue":5.54,"officers":[{"age":65,"name":"Dr. Mihael H. Polymeropoulos M.D.","title":"Founder, President, CEO & Chairman of The Board"},{"age":41,"name":"Mr. Kevin Patrick Moran","title":"Senior VP, CFO & Treasurer"},{"age":59,"name":"Mr. Joakim  Wijkstrom","title":"Senior VP & Chief Marketing Officer"},{"age":56,"name":"Mr. Gunther  Birznieks","title":"Senior Vice President of Business Development"},{"age":50,"name":"Mr. Scott L. Howell","title":"Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.vandapharma.com","phone":"202 734 3400"}}